Journal article
Impact of age on the efficacy and safety of extended-duration thromboprophylaxis in medical patients
Abstract
The EXCLAIM study enrolled hospitalised acutely ill medical patients with age >40 years and recently-reduced mobility into a trial of extended-duration anticoagulant thromboprophylaxis. This post-hocanalysis evaluated the impact of age on patient outcomes. After completion of open-label therapy with enoxaparin 40 mg once-daily (10 ± 4 days), eligible patients underwent randomisation to receive double-blind therapy of enoxaparin (n=2,975) or …
Authors
Yusen RD; Hull RD; Schellong SM; Tapson VF; Monreal M; Samama M-M; Chen M; Deslandes B; Turpie AGG
Journal
Thrombosis and Haemostasis, Vol. 110, No. 06, pp. 1152–1163
Publisher
Thieme
Publication Date
2013
DOI
10.1160/th13-02-0170
ISSN
0340-6245